Physician profile
Mark R Winkle
NPI 1457379240
$1,206.66
in general payments reported to CMS, 2019-2025
19 companies · $274 in 2025
The $274 reported for 2025 was less than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $263 · 2020: $35.83 · 2021: $335 · 2022: $95.15 · 2023: $70.32 · 2024: $133 · 2025: $274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $478.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $477.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $267.72 | 2019-2025 | Scopis Ent |
| Optinose US, INC. | $215.79 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $166.64 | 2021-2024 | Dupixent |
| Glaxosmithkline, LLC. | $82.55 | 2024-2025 | Nucala |
| Xoran Technologies LLC | $60.32 | 2021-2023 | Minicat |
| Merck Sharp & Dohme LLC | $59.35 | 2021-2025 | Keytruda |
| Genzyme Corporation | $47.34 | 2021-2025 | |
| Acclarent, INC | $39.37 | 2022 | |
| Novartis Pharmaceuticals Corporation | $37.47 | 2019 | |
| Medtronic, INC. | $35.03 | 2023 | Sinuva, Propel |
| Integra Lifesciences Corporation | $34.15 | 2024 | Acclarent Aera |
| Inspire Medical Systems, INC. | $33.35 | 2024 | Inspire |
| Olympus America INC. | $28.52 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $24.20 | 2021 | |
| Jazz Pharmaceuticals INC. | $22.35 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascendis Pharma Endocrinology INC | $20.11 | 2025 | Yorvipath |
| Lilly USA, LLC | $14.52 | 2021 | |
| Pfizer INC. | $12.00 | 2019 | |
| Phathom Pharmaceuticals, INC. | $5.88 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Winkle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.